Reply To: Traders Market Weekly: Holiday Shopping Season Kicking Off

#67705
Truman
Participant

Novo Nordisk (NVO 100.18, -1.01, -1.0%): reports Semaglutide 2.4 mg (Wegovy) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine